Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The purpose of this study was to determine: (1) whether stable heart failure patients with reduced ejection fraction (HFrEF) have elevated extravascular lung water (EVLW) when compared with healthy control subjects; and (2) the effect of acute β-adrenergic receptor (βAR) agonist inhalation on lung fluid balance.
Methods: Twenty-two stable HFrEF patients and 18 age- and gender-matched healthy subjects were studied. Lung diffusing capacity for carbon monoxide (DLCO), alveolar-capillary membrane conductance (Dm), pulmonary capillary blood volume (V) (via re-breathe) and lung tissue volume (V) (via computed tomography) were assessed before and within 30 minutes after administration of nebulized albuterol. EVLW was derived as V - V.
Results: Before administration of albuterol, V and EVLW were higher in HFrEF vs control (998 ± 200 vs 884 ± 123 ml, p = 0.041; and 943 ± 202 vs 802 ± 133 ml, p = 0.015, respectively). Albuterol decreased V and EVLW in HFrEF patients (-4.6 ± 7.8%, p = 0.010; -4.6 ± 8.8%, p = 0.018) and control subjects (-2.8 ± 4.9%, p = 0.029; -3.0 ± 5.7%, p = 0.045). There was an inverse relationship between pre-albuterol values and pre- to post-albuterol change for EVLW (r = -0.264, p = 0.015) and Dm (r = -0.343, p = 0.004) in HFrEF only.
Conclusion: Lung fluid is elevated in stable HFrEF patients relative to healthy subjects. Stimulation of βARs may cause fluid removal in HFrEF, especially in patients with greater evidence of increased lung water at baseline.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362291 | PMC |
| http://dx.doi.org/10.1016/j.healun.2016.09.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rationale and Design of the Comparative Effectiveness of ICD Versus Non-ICD Therapy in Contemporary Heart Failure Patients at a Low Risk for Arrhythmic Death (CONTEMP-ICD) trial.
Am Heart J
September 2025
Baylor Scott and White Research Institute and HealthCare, Dallas TX. Electronic address:
Background: Current recommendations for a prophylactic (primary prevention) implantable cardioverter defibrillator (ICD) in patients with both ischemic and non-ischemic heart failure with reduced ejection fraction (HFrEF) originate from clinical trials conducted in selected patients over 20 years ago that showed an overall statistically significant survival benefit associated with a primary prevention ICD in the range of 23%-34%. The recent introduction of angiotensin receptor-neprilysin inhibitors [ARNI] and sodium glucose co-transporter 2 inhibitors [SGLT2i]) was shown to further reduce the risk of sudden cardiac death (SCD) in patients with HFrEF. Thus, there is an unmet need appropriately designed comparative effectiveness clinical trials aimed to reassess the survival benefit of a primary prevention ICD in contemporary patients with HFrEF.
View Article and Find Full Text PDFPrevalence and importance of coronary microvascular dysfunction in patients with heart failure and reduced or mildly reduced ejection fraction.
Open Heart
September 2025
Cardiology Department, Sahlgrenska University Hospital, Gothenburg, Sweden.
Aims: We investigated the prevalence of coronary microvascular dysfunction (CMD) and its association with severity of heart failure in patients with reduced or mildly reduced ejection fraction (HFrEF and HFmrEF).
Method: Patients with stable, symptomatic heart failure with left ventricular ejection fraction (LVEF) <50% were enrolled. Data collection included physical examination, blood samples, Kansas City Cardiomyopathy Questionnaire (KCCQ), carotid to femoral pulse wave velocity, echocardiography and adenosine-based transthoracic Doppler echocardiography to assess coronary flow reserve (CFR).
Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction.
Circ Heart Fail
September 2025
Canadian VIGOUR Centre, University of Alberta, Edmonton. (R.M., N.S., J.A.E.).
Background: Although the effects of various combinations of treatments on mortality and morbidity outcomes in heart failure with reduced ejection fraction (HFrEF) have been evaluated, the impact on quality of life is unknown. This study evaluated and compared the composite impact of pharmacological therapies on quality of life in HFrEF using a frequentist network meta-analysis and systematic review methodology.
Methods: We searched MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials for randomized controlled trials published between January 1, 2021 and August 10, 2024.
Re-PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients.
ESC Heart Fail
September 2025
Division of Cardiology, Department of Medicine, Karolinska Institutet, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Aims: Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long-acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family peptide receptor 1 (RXFP1), showed trends of increased stroke volume and estimated glomerular filtration rate (eGFR) in HF patients (NCT04630067).
View Article and Find Full Text PDFDrug treatment of chronic heart failure with reduced ejection fraction.
Drug Ther Bull
September 2025
King's College Hospital NHS Foundation Trust, London, UK.
Heart failure (HF) is a progressive clinical syndrome characterised by insufficient cardiac output due to structural and functional abnormalities of the heart, which can then lead to breathlessness, fatigue and fluid overload. HF has an associated high morbidity and mortality rate as well as a significant impact on healthcare resources; for example, in the UK, it accounts for 5% of National Health Service (NHS) emergency admissions. This review focuses on pharmacological treatment of chronic HF with reduced ejection fraction (HFrEF), which affects approximately 60% of patients with HF.
View Article and Find Full Text PDF